Journal of Blood Medicine
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Newer agents in antiplatelet therapy: a review
(8339) Total Article Views
Authors: Yeung J, Holinstat M
Published Date June 2012
Volume 2012:3 Pages 33 - 42
|Received:||01 May 2012|
|Accepted:||17 May 2012|
|Published:||25 June 2012|
Cardeza Foundation for Hematologic Research, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Abstract: Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although there has been significant advancement in antiplatelet therapeutic approaches, aspirin still remains the gold standard treatment in the clinical setting. Limitations in safety, efficacy, and tolerability have precluded many of the antiplatelet inhibitors from use in patients. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies. The pharmacokinetic and pharmacodynamic profiles have also limited the effectiveness of a number of antiplatelet inhibitors currently in use due to variability in metabolism, time to onset, and reversibility. A focused effort in the development of newer antiplatelet therapies to address some of these shortcomings has resulted in a significant number of potential antiplatelet drugs which target enzymes (phosphodiesterase, cyclooxygenase), receptors (purinergic, prostaglandins, protease-activated receptors, thromboxane), and glycoproteins (αIIbß3, GPVI, vWF, GPIb) in the platelet. The validation and search for newer antiplatelet therapeutic approaches proven to be superior to aspirin is still ongoing and should yield a better pharmacodynamic profile with fewer untoward side-effects to what is currently in use today.
Keywords: platelet aggregation inhibitors, blood platelets, purinergic P2Y receptor antagonists, receptor, PAR-1, platelet glycoprotein GPIIb-IIIa, thrombosis
Erratum for this paper has been published.
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Michael Holinstat
Readers of this article also read:
Call For Submissions
Submit Original Research Article, Review, Case Report, or Rapid Communication in Journal of Blood Medicine
- Treatment of anemia in chronic kidney disease: known, unknown, and both
- Treatment of hemophilia: a review of current advances and ongoing issues
- Use of sulodexide in patients with peripheral vascular disease
- Deep vein thrombosis: a clinical review